Allostatic load as a tool for monitoring physiological dysregulations and comorbidities in patients with severe mental Illnesses

Harvard Review of Psychiatry

Volumn 21, Issue 6, 2013, Pages 296-313

  Bizik, Gustav ^a   Picard, Martin ^b   Nijjar, Rami ^c   Tourjman, Valérie ^d,e   McEwen, Bruce S ^g,h   Lupien, Sonia J ^d,e,f   Juster, Robert Paul ^a,e,f,i  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Civil and Environmental Engineering   (Canada)

^d Department of Psychiatry ^*  (Spain)

^e CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^f Center for Studies on Human Stress   (Spain)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

^h ROCKEFELLER UNIVERSITY   (United States)

ⁱ MCGILL UNIVERSITY   (Canada)

Author keywords

Allostatic load; Bipolar disorder; Chronic stress; Comorbidities; Pharmacological allostatic load; Schizophrenia; Severe mental illness

Indexed keywords

BIOLOGICAL MARKER; PSYCHOTROPIC AGENT;

ALLOSTASIS; ALLOSTATIC LOAD; BEHAVIOR; CHRONIC STRESS; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; COGNITIVE DEFECT; COMORBIDITY; DISEASE SEVERITY; HUMAN; IATROGENIC DISEASE; MENTAL DISEASE; NONHUMAN; PATIENT MONITORING; PHYSICIAN; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; REVIEW;

ALLOSTASIS; COMORBIDITY; HUMANS; MENTAL DISORDERS; SEVERITY OF ILLNESS INDEX;

EID: 84896741081     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1097/HRP.0000000000000012     Document Type: Review

References (210)

1. Brundtland GH. From the World Health Organization. Mental health: new understanding, new hope. JAMA 2001; 286:2391.
2. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ. Cardiovascular disease and diabetes in people with severe mental illness: position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24: 412-24.
3. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64:1123-31.
4. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002;68:167-81.
5. Seeman TE, Singer BH, Rowe JW, Horwitz RI, McEwen BS. Price of adaptation - allostatic load and its health consequences. MacArthur studies of successful aging. Arch Intern Med 1997;157:2259-68.
6. Beckie TM. A systematic review of allostatic load, health, and health disparities. Biol Res Nurs 2012;14:311-46.
7. Juster RP, McEwen BS, Lupien SJ. Allostatic load biomarkers of chronic stress and impacton health and cognition. Neurosci Biobehav Rev 2010;35:2-16.
8. Kapczinski F, Vieta E, Andreazza AC, et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev 2008;32:675-92.
9. Sterling P, Eyer J. Allostasis: a new paradigm to explain arousal pathology. In: Fisher S, Reason J, eds. Handbook of life stress, cognition and health. New York: Wiley, 1988:629-49.
10. Sterling P. Principles of allostasis: optimal design, predictive regulation, pathophysiology and rational therapeutics. In: Schulkin J, ed. Allostasis, homeostasis, and the costs of adaptation. Cambridge: Cambridge University Press, 2004:17-64.
11. Schulkin J. Allostasis: a neural behavioral perspective. Horm Behav 2003;43:21-7; discussion 8-30.
12. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 2000;21:55-89.
13. McEwen BS. Stress, adaptation, and disease. Allostasis and allostatic load. Ann N Y Acad Sci 1998;840:33-44.
14. McEwen BS, Stellar E. Stress and the individual. Mechanisms leading to disease. Arch Intern Med 1993;153:2093-101.
15. McEwen BS. Allostasis and allostatic load: implications for neuropsychopharmacology. Neuropsychopharmacology 2000;22:108-24.
16. Juster RP, Lupien SJ. Chronic stress and allostatic load. In: Schenck-Gustafsson K, DeCola PR, Pfaff DW, Pisetsky DS, eds. Handbook of clinical gender medicine. Basel: Karger, 2012:70-81.
17. Seeman E, Singer BH, Rowe J, Horwitz RI, McEwen B. Price of adaptation - allostatic load and its health consequences. Arch Intern Med 1997;157:2259-68.
18. Gruenewald TL, Mroczek DK, Ryff CD, Singer BH. Diverse pathways to positive and negative affect in adulthood and later life: an integrative approach using recursive partitioning. Dev Psychol 2008;44:330-43.
19. Seeman TE, McEwen BS, Rowe JW, Singer BH. Allostatic load as a marker of cumulative biological risk: MacArthur studies of successful aging. Proc Natl Acad Sci U S A 2001;98: 4770-5.
20. Goldman N, Turra CM, Glei DA, Lin YH, Weinstein M. Physiological dysregulation and changes in health in an older population. Exp Gerontol 2006;41:862-70.
21. Goldman N, Turra CM, Glei DA, Seplaki CL, Lin YH, Weinstein M. Predicting mortality from clinical and nonclinical biomarkers. J Gerontol A Biol Sci Med Sci 2006;61:1070-4.
22. Seplaki CL, Goldman N, Glei D, Weinstein M. A comparative analysis of measurement approaches for physiological dysregulation in an older population. Exp Gerontol 2005;40:438-49.
23. Seplaki CL, Goldman N, Weinstein M, Lin YH. How are biomarkers related to physical and mental well-being? J Gerentol 2004;59A:201-17.
24. Seplaki CL, Goldman N, Weinstein M, Lin YH. Measurement of cumulative physiological dysregulation in an older population. Demography 2006;43:165-83.
25. Karlamangla AS, Singer BH, Seeman TE. Reduction in allostatic load in older adults is associated with lower allcause mortality risk: MacArthur studies of successful aging. Psychosom Med 2006;68:500-7.
26. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, et al. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry 2008;69:514-9.
27. Brown S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry 1997;171:502-8.
28. Newcomer JW. Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry 2006;67 suppl 9:25-30; discussion 36-42.
29. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ 2000;321:483-4.
30. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150:1115-21.
31. Holt RI, Bushe C, Citrome L. Diabetes and schizophrenia 2005: are we any closer to understanding the link? J Psychopharmacol 2005;19:56-65.
32. McIntyre RS, Konarski JZ, Misener VL, Kennedy SH. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 2005;17:83-93.
33. McEwen BS. Interacting mediators of allostasis and allostatic load: towards an understanding of resilience in aging. Metabolism 2003;52:10-6.
34. McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med 1998;338:171-9.
35. Muck-Seler D, Pivac N, Mustapic M, Crncevic Z, Jakovljevic M, Sagud M. Platelet serotonin and plasma prolactin and cortisol in healthy, depressed and schizophrenic women. Psychiatry Res 2004;127:217-26.
36. Walsh P, Spelman L, Sharifi N, Thakore JH. Male patients with paranoid schizophrenia have greater ACTH and cortisol secretion in response to metoclopramide-induced AVP release. Psychoneuroendocrinology 2005;30:431-7.
37. Gallagher P, Watson S, Smith MS, Young AH, Ferrier IN. Plasma cortisol-dehydroepiandrosterone (DHEA) ratios in schizophrenia and bipolar disorder. Schizophr Res 2007;90: 258-65.
38. Ritsner M, Gibel A, Maayan R, et al. State and trait related predictors of serum cortisol to DHEA(S) molar ratios and hormone concentrations in schizophrenia patients. Eur Neuropsychopharmacol 2007;17:257-64.
39. Yilmaz N, Herken H, Cicek HK, Celik A, Yurekli M, Akyol O. Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia. Med Princ Pract 2007;16:137-41.
40. Linkowski P, Kerkhofs M, Van Onderbergen A, et al. The 24-hour profiles of cortisol, prolactin, and growth hormone secretion in mania. Arch Gen Psychiatry 1994;51:616-24.
41. Muck-Seler D, Pivac N, Jakovljevic M, Brzovic Z. Platelet serotonin, plasma cortisol, and dexamethasone suppression test in schizophrenic patients. Biol Psychiatry 1999;45:1433-9.
42. Ismail K, Murray RM, Wheeler MJ, O'Keane V. The dexamethasone suppression test in schizophrenia. Psychol Med 1998;28:311-7.
43. Sher L. Combined dexamethasone suppression-corticotropin-releasing hormone stimulation test in studies of depression, alcoholism, and suicidal behavior. ScientificWorldJournal 2006;6:1398-404.
44. Watson S, Gallagher P, Ritchie JC, Ferrier IN, Young AH. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry 2004;184:496-502.
45. Vieta E, Gasto C, Martinez de Osaba MJ, et al. Prediction of depressive relapse in remitted bipolar patients using corticotrophin-releasing hormone challenge test. Acta Psychiatr Scand 1997;95:205-11.
46. Maninger N, Wolkowitz OM, Reus VI, Epel ES, Mellon SH. Neurobiological and neuropsychiatric effects of dehydroepi-androsterone (DHEA) and DHEA sulfate (DHEAS). Front Neuroendocrinol 2009;30:65-91.
47. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008;63: 801-8.
48. Breunis MN, Kupka RW, Nolen WA, et al. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol Psychiatry 2003;53:157-65.
49. Kim YK, Jung HG, Myint AM, Kim H, Park SH. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 2007;104:91-5.
50. Liu HC, Yang YY, Chou YM, Chen KP, Shen WW, Leu SJ. Immunologic variables in acute mania of bipolar disorder. J Neuroimmunol 2004;150:116-22.
51. O'Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord 2006;90:263-7.
52. Ortiz-Dominguez A, Hernandez ME, Berlanga C, et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord 2007;9:596-602.
53. Tsai SY, Chen KP, Yang YY, et al. Activation of indices of cell-mediated immunity in bipolar mania. Biol Psychiatry 1999;45:989-94.
54. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92: 347-55.
55. Bob P, Raboch J, Maes M, et al. Depression, traumatic stress and interleukin-6. J Affect Disord 2010;120:231-4.
56. Goldstein BI, Fagiolini A, Houck P, Kupfer DJ. Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord 2009;11:657-62.
57. Fleet-Michaliszyn SB, Soreca I, Otto AD, et al. A prospective observational study of obesity, body composition, and insulin resistance in 18 women with bipolar disorder and 17 matched control subjects. J Clin Psychiatry 2008;69:1892-900.
58. Fagiolini A, Frank E, Turkin S, Houck PR, Soreca I, Kupfer DJ. Metabolic syndrome in patients with bipolar disorder. J Clin Psychiatry 2008;69:678-9.
59. Trushina E, McMurray CT. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience 2007; 145:1233-48.
60. Juster RP, Bizik G, Picard M, et al. A transdisciplinary perspective of chronic stress in relation to psychopathology throughout life span development. Dev Psychopathol 2011; 23:725-76.
61. Anisman H, Hayley S. Illness comorbidity as a biomarker? J Psychiatry Neurosci 2012;37:221-3.
62. Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull 2009;35: 383-402.
63. Krishnan KR. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med 2005;67:1-8.
64. McElroy SL, Altshuler LL, Suppes T, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001; 158:420-6.
65. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264:2511-8.
66. George O, Le Moal M, Koob GF. Allostasis and addiction: role of the dopamine and corticotropin-releasing factor systems. Physiol Behav 2012;106:58-64.
67. Koob GF. Alcoholism: allostasis and beyond. Alcohol Clin Exp Res 2003;27:232-43.
68. Koob GF, Ahmed SH, Boutrel B, et al. Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev 2004;27:739-49.
69. Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001;24: 97-129.
70. Schulkin J. Addiction to drugs: allostatic regulation under duress. In: Rethinking homestasis: allostatic regulation in physiology and pathophysiology. Cambridge, MA: MIT, 2003:131-60.
71. Valdez GR, Koob GF. Allostasis and dysregulation of corticotropin- releasing factor and neuropeptide Y systems: implications for the development of alcoholism. Pharmacol Biochem Behav 2004;79:671-89.
72. Grande I, Magalhaes PV, Kunz M, Vieta E, Kapczinski F. Mediators of allostasis and systemic toxicity in bipolar disorder. Physiol Behav 2012;106:46-50.
73. McEwen BS. Mood disorders and allostatic load. Biol Psychiatry 2003;54:200-7.
74. McEwen BS. Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism 2005;54:20-3.
75. McEwen BS. Protection and damage from acute and chronic stress: allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders. Ann N Y Acad Sci 2004;1032:1-7.
76. Schulkin J, Gold PW, McEwen BS. Induction of corticotropin-releasing hormone gene expression by glucocorticoids: implication for understanding the states of fear and anxiety and allostatic load. Psychoneuroendocrinology 1998;23: 219-43.
77. Schulkin J, McEwen BS, Gold PW. Allostasis, amygdala, and anticipatory angst. Neurosci Biobehav Rev 1994;18:385-96.
78. McEwen BS. The neurobiology and neuroendocrinology of stress. Implications for post-traumatic stress disorder from a basic science perspective. Psychiatr Clin North Am 2002;25: 469-94, ix.
79. Birmaher B, Kennah A, Brent D, Ehmann M, Bridge J, Axelson D. Is bipolar disorder specifically associated with panic disorder in youths? J Clin Psychiatry 2002;63:414-9.
80. MacQueen GM, Marriott M, Begin H, Robb J, Joffe RT, Young LT. Subsyndromal symptoms assessed in longitudinal, prospective follow-up of a cohort of patients with bipolar disorder. Bipolar Disord 2003;5:349-55.
81. Elman I, Borsook D, Lukas SE. Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology 2006;31: 2091-120.
82. Dallman MF, Pecoraro N, Akana SF, et al. Chronic stress and obesity: a new view of "comfort food." Proc Natl Acad Sci U S A 2003;100:11696-701.
83. Vieta E, Popovic D, Rosa AR, et al. The clinical implications of cognitive impairment and allostatic load in bipolar disorder. Eur Psychiatry 2013; 28:21-9.
84. Abler B, Greenhouse I, Ongur D, Walter H, Heckers S. Abnormal reward system activation in mania. Neuropsychopharmacology 2008;33:2217-27.
85. Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des 2009;15:2550-9.
86. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003;160:13-23.
87. Kapur S, Agid O, Mizrahi R, Li M. How antipsychotics work - from receptors to reality. NeuroRx 2006;3:10-21.
88. Paradiso S, Andreasen NC, Crespo-Facorro B, et al. Emotions in unmedicated patients with schizophrenia during evaluation with positron emission tomography. Am J Psychiatry 2003; 160:1775-83.
89. Gur RE, McGrath C, Chan RM, et al. An fMRI study of facial emotion processing in patients with schizophrenia. Am J Psychiatry 2002;159:1992-9.
90. Sturm R. The effects of obesity, smoking, and drinking on medical problems and costs. Health Aff (Millwood) 2002; 21:245-53.
91. Lopresti AL, Drummond PD. Obesity and psychiatric disorders: commonalities in dysregulated biological pathways and their implications for treatment. Prog Neuropsychopharmacol Biol Psychiatry 2013;45:92-9.
92. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999;29: 697-701.
93. Strassnig M, Brar JS, Ganguli R. Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophr Bull 2003;29:393-7.
94. McCreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003;183:534-9.
95. Peet M. Diet, diabetes and schizophrenia: review and hypothesis. Br J Psychiatry Suppl 2004;47:S102-5.
96. Anderson EJ, Lustig ME, Boyle KE, et al. Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 2009;119:573-81.
97. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 2005;39:359-407.
98. Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 2001;50:71-83.
99. Krystal JH, D'Souza DC, Gallinat J, et al. The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia. Neurotox Res 2006;10:235-52.
100. Fagen ZM, Mitchum R, Vezina P, McGehee DS. Enhanced nicotinic receptor function and drug abuse vulnerability. J Neurosci 2007;27:8771-8.
101. De Hert M, Schreurs V, Vancampfort D, van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009;8:15-22.
102. Mueser KT, Bellack AS, Blanchard JJ. Comorbidity of schizophrenia and substance abuse: implications for treatment. J Consult Clin Psychol 1992;60:845-56.
103. Mobascher A, Winterer G. The molecular and cellular neurobiology of nicotine abuse in schizophrenia. Pharmacopsychiatry 2008;41 suppl 1:S51-9.
104. Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995;38:22-33.
105. Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl) 2006;184:523-39.
106. Adler LE, Hoffer LD, Wiser A, Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993;150:1856-61.
107. Harris JG, Kongs S, Allensworth D, et al. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 2004;29:1378-85.
108. Myers CS, Robles O, Kakoyannis AN, et al. Nicotine improves delayed recognition in schizophrenic patients. Psychopharmacology (Berl) 2004;174:334-40.
109. de Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry 1995;152: 453-5.
110. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 1997;390:401-4.
111. Cardenas L, Tremblay LK, Naranjo CA, Herrmann N, Zack M, Busto UE. Brain reward system activity in major depression and comorbid nicotine dependence. J Pharmacol Exp Ther 2002;302:1265-71.
112. Goswami S, Mattoo SK, Basu D, Singh G. Substance-abusing schizophrenics: do they self-medicate? Am J Addict 2004;13: 139-50.
113. Juckel G, Sass L, Heinz A. Anhedonia, self-experience in schizophrenia, and implications for treatment. Pharmacopsychiatry 2003;36 suppl 3:S176-80.
114. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 1999;36:425-38.
115. Zaslove MO, Russell RL, Ross E. Effect of caffeine intake on psychotic in-patients. Br J Psychiatry 1991;159:565-7.
116. Hughes JR, McHugh P, Holtzman S. Caffeine and schizophrenia. Psychiatr Serv 1998;49:1415-7.
117. de Leon J. Atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatr Serv 2004;55:491-3.
118. Haskell CF, Kennedy DO, Wesnes KA, Scholey AB. Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. Psychopharmacology (Berl) 2005;179:813-25.
119. Tanda G, Goldberg SR. Alteration of the behavioral effects of nicotine by chronic caffeine exposure. Pharmacol Biochem Behav 2000;66:47-64.
120. Adolfo AB, AhnAllen CG, Tidey JW. Effectsofsmoking cues on caffeine urges in heavy smokers and caffeine consumers with and without schizophrenia. Schizophr Res 2009;107:192-7.
121. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006;86:15-22.
122. De Hert M, Falissard B, Mauri M, Shaw K, Wetterling T. Epidemiological study for the evaluation of metabolic disorders in patients with schizophrenia: the METEOR Study. Eur Neuropsychopharmacol 2008;18(suppl 4):S444.
123. Laursen TM, Munk-Olsen T, Agerbo E, Gasse C, Mortensen PB. Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry 2009;66:713-20.
124. Jeste DV, Gladsjo JA, Lindamer LA, Lacro JP. Medical comorbidity in schizophrenia. Schizophr Bull 1996;22: 413-30.
125. Lublin H, Eberhard J, Levander S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharmacol 2005;20:183-98.
126. Haddad PM, Sharma SG. Adverse effects of atypical anti-psychotics: differential risk and clinical implications. CNS Drugs 2007;21:911-36.
127. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519-26.
128. Muller DJ, Muglia P, Fortune T, Kennedy JL. Pharmacogenetics of antipsychotic-induced weight gain. Pharmacol Res 2004;49:309-29.
129. Ellingrod VL, Perry PJ, Ringold JC, et al. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 2005;134B:76-8.
130. Picard M, Turnbull DM. Linking the metabolic state and mitochondrial DNA in chronic disease, health and aging. Diabetes 2013 (forthcoming).
131. Handschin C, Spiegelman BM. The role of exercise and PGC1alpha in inflammation and chronic disease. Nature 2008; 454:463-9.
132. Wei M, Kampert JB, Barlow CE, et al. Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men. JAMA 1999;282: 1547-53.
133. Hu FB, Willett WC, Li T, Stampfer MJ, Colditz GA, Manson JE. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med 2004;351: 2694-703.
134. Gustafson D. A life course of adiposity and dementia. Eur J Pharmacol 2008;585:163-75.
135. Mattson MP. Energy intake and exercise as determinants of brain health and vulnerability to injury and disease. Cell Metab 2012;16:706-22.
136. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19 suppl 1:1-93.
137. Saari K, Koponen H, Laitinen J, et al. Hyperlipidemia in persons using antipsychotic medication: a general population-based birth cohort study. J Clin Psychiatry 2004;65:547-50.
138. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004;64:701-23.
139. Vendsborg PB, Bech P, Rafaelsen OJ. Lithium treatment and weight gain. Acta Psychiatr Scand 1976;53:139-47.
140. Swann AC. Major system toxicities and side effects of anticonvulsants. J Clin Psychiatry 2001;62 suppl 14:16-21.
141. Manderbacka K, Sund R, Koski S, Keskimaki I, Elovainio M. Diabetes and depression? Secular trends in the use of antidepressants among persons with diabetes in Finland in 1997-2007. Pharmacoepidemiol Drug Saf 2011;20:338-43.
142. Awad AG. Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disorders. Expert Rev Pharmacoecon Outcomes Res 2010;10:1-4.
143. Voruganti LP, Awad AG. Is neuroleptic dysphoria a variant of drug-induced extrapyramidal side effects? Can J Psychiatry 2004;49:285-9.
144. Tandon R. Safety and tolerability: how do newer generation "atypical" antipsychotics compare? Psychiatr Q 2002;73: 297-311.
145. Mizrahi R, Rusjan P, Agid O, et al. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am J Psychiatry 2007;164:630-7.
146. Voruganti LNP, Awad AG. Role of dopamine in pleasure, reward and subjective responses to drugs. The neuropsycho-pharmacology of quality of life in schizophrenia. In: Ritsner MS, Awad AG, eds. Quality of life impairment in schizophrenia, mood and anxiety disorders. Dordrecht: Springer, 2007.
147. de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans PM, Linszen D. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry 2003;160:303-9.
148. Kapur S, Remington G, Jones C, et al. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996;153:948-50.
149. Nordstrom AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-35.
150. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 2000;25:161-6.
151. Voruganti LN, Heslegrave RJ, Awad AG. Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. J Nerv Ment Dis 1997;185:463-5.
152. Noordsy DL, Green AI. Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Curr Psychiatry Rep 2003;5:340-6.
153. Kosten TA, Nestler EJ. Clozapine attenuates cocaine conditioned place preference. Life Sci 1994;55:PL9-14.
154. Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res 2001;107:173-7.
155. Breier A, Su TP, Saunders R, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 1997;94:2569-74.
156. Laruelle M, Abi-Dargham A, van Dyck CH, et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 1995;36:1182-90.
157. Schlaepfer TE, Pearlson GD, Wong DF, Marenco S, Dannals RF. PET study of competition between intravenous cocaine and [11C]raclopride at dopamine receptors in human subjects. Am J Psychiatry 1997;154:1209-13.
158. D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005; 57:594-608.
159. Munro CA, McCaul ME, Oswald LM, et al. Striatal dopamine release and family history of alcoholism. Alcohol Clin Exp Res 2006;30:1143-51.
160. Oswald LM, Wong DF, McCaul M, et al. Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. Neuropsychopharmacology 2005;30:821-32.
161. Peretti CS, Danion JM, Kauffmann-Muller F, Grange D, Patat A, Rosenzweig P. Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers. Psychopharmacology (Berl) 1997;131:329-38.
162. Saeedi H, Remington G, Christensen BK. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophr Res 2006;85:222-31.
163. Kim SH, Han DH, Joo SY, Min KJ. The effect of dopamine partial agonists on the nicotine dependency in patients with schizophrenia. Hum Psychopharmacol 2010;25:187-90.
164. de Haan L, Booij J, Lavalaye J, van Amelsvoort T, Linszen D. Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia. Psychopharmacology (Berl) 2006;183:500-5.
165. McEvoy J, Freudenreich O, McGee M, VanderZwaag C, Levin E, Rose J. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry 1995;37:550-2.
166. Li S, Kim KY, Kim JH, Park MS, Bahk JY, Kim MO. Chronic nicotine and smoking treatment increases dopamine transporter mRNA expression in the rat midbrain. Neurosci Lett 2004;363:29-32.
167. Drew AE, Werling LL. Nicotinic receptor-mediated regulation of the dopamine transporter in rat prefrontocortical slices following chronic in vivo administration of nicotine. Schizophr Res 2003;65:47-55.
168. Yang YK, Nelson L, Kamaraju L, Wilson W, McEvoy JP. Nicotine decreases bradykinesia-rigidity in haloperidoltreated patients with schizophrenia. Neuropsychopharmacology 2002;27:684-6.
169. Anfang MK, Pope HG Jr. Treatment of neuroleptic-induced akathisia with nicotine patches. Psychopharmacology (Berl) 1997;134:153-6.
170. Goff DC, Henderson DC, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 1992;149:1189-94.
171. Silvestri S, Negrete JC, Seeman MV, Shammi CM, Seeman P. Does nicotine affect D2 receptor upregulation? A case-control study. Acta Psychiatr Scand 2004;109:313-7; discussion 7-8.
172. Seeman P. Tardive dyskinesia, dopamine receptors, and neuroleptic damage to cell membranes. J Clin Psychopharmacol 1988;8:3S-9S.
173. Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 2004;161:116-24.
174. Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollock BG. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry 2009;166:1055-62.
175. Levin ED, Wilson W, Rose JE, McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 1996;15:429-36.
176. Strand JE, Nyback H. Tobacco use in schizophrenia: a study of cotinine concentrations in the saliva of patients and controls. Eur Psychiatry 2005;20:50-4.
177. de Leon J, Diaz FJ, Aguilar MC, Jurado D, Gurpegui M. Does smoking reduce akathisia? Testing a narrow version of the self-medication hypothesis. Schizophr Res 2006;86: 256-68.
178. Lorberg B, Wilens TE, Martelon M, Wong P, Parcell T. Reasons for substance use among adolescents with bipolar disorder. Am J Addict 2010;19:474-80.
179. Schreiber S, Backer MM, Weizman R, Pick CG. Augmentation of opioid induced antinociception by the atypical antipsychotic drug risperidone in mice. Neurosci Lett 1997; 228:25-8.
180. Schreiber S, Getslev V, Backer MM, Weizman R, Pick CG. The atypical neuroleptics clozapine and olanzapine differ regarding their antinociceptive mechanisms and potency. Pharmacol Biochem Behav 1999;64:75-80.
181. Weizman T, Pick CG, Backer MM, Rigai T, Bloch M, Schreiber S. The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. Eur J Pharmacol 2003;478:155-9.
182. Fe-Bornstein M, Watt SD, Gitlin MC. Improvement in the level of psychosocial functioning in chronic pain patients with the use of risperidone. Pain Med 2002;3:128-31.
183. Kiser RS, Cohen HM, Freedenfeld RN, Jewell C, Fuchs PN. Olanzapine for the treatment of fibromyalgia symptoms. J Pain Symptom Manage 2001;22:704-8.
184. Silberstein SD, Peres MF, Hopkins MM, Shechter AL, Young WB, Rozen TD. Olanzapine in the treatment of refractory migraine and chronic daily headache. Headache 2002;42:515-8.
185. Marchesi GF, Santone G, Cotani P, Giordano A, Chelli F. The therapeutic role of naltrexone in negative symptom schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:1239-49.
186. Kelley AE, Bakshi VP, Haber SN, Steininger TL, Will MJ, Zhang M. Opioid modulation of taste hedonics within the ventral striatum. Physiol Behav 2002;76:365-77.
187. Will MJ, Franzblau EB, Kelley AE. Nucleus accumbens muopioids regulate intake of a high-fat diet via activation of a distributed brain network. J Neurosci 2003;23:2882-8.
188. Petrakis IL, O'Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal JH. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl) 2004;172:291-7.
189. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-7.
190. Haroun N, Dunn L, Haroun A, Cadenhead KS. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future
191. McGlashan TH, Zipursky RB, Perkins D, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790-9.
192. Miller TJ, Zipursky RB, Perkins D, et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophr Res 2003;61:19-30.
193. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull 2008;34:523-37.
194. Wirshing DA, Smith RA, Erickson ZD, Mena SJ, Wirshing WC. A wellness class for inpatients with psychotic disorders. J Psychiatr Pract 2006;12:24-9.
195. Wreeland B, Minski S, Menza M, Radler DR, Roemheld-Hamm B, Stern R. A program for managing weight gain associated with atypical antipsychotics. Psychiatr Serv 2003; 54:1155-7.
196. Robson D, Gray R. Serious mental illness and physical health problems: a discussion paper. Int J Nurs Stud 2007; 44:457-66.
197. Spolidoro M, Baroncelli L, Putignano E, Maya-Vetencourt JF, Viegi A, Maffei L. Food restriction enhances visual cortex plasticity in adulthood. Nat Commun 2011;2:320.
198. Seifert T, Brassard P, Wissenberg M, et al. Endurance training enhances BDNF release from the human brain. Am J Physiol Regul Integr Comp Physiol 2010;298:R372-7.
199. Steiner JL, Murphy EA, McClellan JL, Carmichael MD, Davis JM. Exercise training increases mitochondrial biogenesis in the brain. J Appl Physiol 2011;111:1066-71.
200. Archie SM, Goldberg JO, Akhtar-Danesh N, Landeen J, McColl L, McNiven J. Psychotic disorders, eating habits, and physical activity: who is ready for lifestyle changes? Psychiatr Serv 2007;58:233-9.
201. Twamley EW, Jeste DV, Lehman AF. Vocational rehabilitation in schizophrenia and other psychotic disorders: a literature review and meta-analysis of randomized controlled trials. J Nerv Ment Dis 2003;191:515-23.
202. Nose M, Barbui C, Gray R, Tansella M. Clinical interventions for treatment non-adherence in psychosis: meta-analysis. Br J Psychiatry 2003;183:197-206.
203. Burns T, Catty J, Dash M, Roberts C, Lockwood A, Marshall M. Use of intensive case management to reduce time in hospital in people with severe mental illness: systematic review and meta-regression. BMJ 2007;335:336.
204. Afshar H, Roohafza H, Mousavi G, et al. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebocontrolled clinical trial. J Psychopharmacol 2009;23:157-62.
205. Levy E, Agbokou C, Ferreri F, Chouinard G, Margolese HC. Topiramate-induced weight loss in schizophrenia: a retrospective case series study. Can J Clin Pharmacol 2007;14:e234-9.
206. Raine A, Mellingen K, Liu J, Venables P, Mednick SA. Effects of environmental enrichment at ages 3-5 years on schizotypal personality and antisocial behavior at ages 17 and 23 years. Am J Psychiatry 2003;160:1627-35.
207. Kandel ER. Biology and the future of psychoanalysis: a new intellectual framework for psychiatry revisited. Am J Psychiatry 1999;156:505-24.
208. Vinogradov S, Fisher M, Holland C, Shelly W, Wolkowitz O, Mellon SH. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia? Biol Psychiatry 2009;66:549-53.
209. Cicchetti D, Gunnar MR. Integrating biological measures into the design and evaluation of preventive interventions. Dev Psychopathol 2008;20:737-43.
210. McEwen BS. Central effects of stress hormones in health and disease: understanding the protective and damaging effects of stress and stress mediators. Eur J Pharmacol 2008;583:174-85.